A citation-based method for searching scientific literature

Yuto Yasuda, Hiroaki Ozasa, Young Hak Kim. J Thorac Oncol 2018
Times Cited: 23







List of co-cited articles
149 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Leora Horn, Aaron S Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J Hochmair, Florian Huemer, György Losonczy, Melissa L Johnson, Makoto Nishio,[...]. N Engl J Med 2018
56

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
Patrick A Ott, Elena Elez, Sandrine Hiret, Dong-Wan Kim, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Janice M Mehnert. J Clin Oncol 2017
284
52

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Scott J Antonia, José A López-Martin, Johanna Bendell, Patrick A Ott, Matthew Taylor, Joseph Paul Eder, Dirk Jäger, M Catherine Pietanza, Dung T Le, Filippo de Braud,[...]. Lancet Oncol 2016
763
52

PD-L1 expression in small cell neuroendocrine carcinomas.
Anne M Schultheis, Andreas H Scheel, Luka Ozretić, Julie George, Roman K Thomas, Thorsten Hagemann, Thomas Zander, Jürgen Wolf, Reinhard Buettner. Eur J Cancer 2015
161
39

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).
Shirish M Gadgeel, Nathan A Pennell, Mary Jo Fidler, Balazs Halmos, Philip Bonomi, James Stevenson, Bryan Schneider, Ammar Sukari, Jaclyn Ventimiglia, Wei Chen,[...]. J Thorac Oncol 2018
116
39

Comprehensive genomic profiles of small cell lung cancer.
Julie George, Jing Shan Lim, Se Jin Jang, Yupeng Cun, Luka Ozretić, Gu Kong, Frauke Leenders, Xin Lu, Lynnette Fernández-Cuesta, Graziella Bosco,[...]. Nature 2015
988
34

Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.
Hidenobu Ishii, Koichi Azuma, Akihiko Kawahara, Kazuhiko Yamada, Yohei Imamura, Takaaki Tokito, Takashi Kinoshita, Masayoshi Kage, Tomoaki Hoshino. J Thorac Oncol 2015
131
30

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
Hui Yu, Cory Batenchuk, Andrzej Badzio, Theresa A Boyle, Piotr Czapiewski, Daniel C Chan, Xian Lu, Dexiang Gao, Kim Ellison, Ashley A Kowalewski,[...]. J Thorac Oncol 2017
75
30

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Luis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J Hochmair, Mustafa Özgüroğlu, Jun Ho Ji,[...]. Lancet 2019
538
30

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
26

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Louis Fehrenbacher, Alexander Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazieres, Keunchil Park, David Smith, Angel Artal-Cortes, Conrad Lewanski,[...]. Lancet 2016
26

PD-L1 expression in small cell lung cancer.
Takefumi Komiya, Rashna Madan. Eur J Cancer 2015
25
26

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Martin Reck, Alexander Luft, Aleksandra Szczesna, Libor Havel, Sang-We Kim, Wallace Akerley, Maria Catherine Pietanza, Yi-Long Wu, Christoph Zielinski, Michael Thomas,[...]. J Clin Oncol 2016
276
26

Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
Kentaro Inamura, Yusuke Yokouchi, Maki Kobayashi, Hironori Ninomiya, Rie Sakakibara, Makoto Nishio, Sakae Okumura, Yuichi Ishikawa. Cancer Med 2017
33
26

Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.
Hye Sook Kim, Jeong Hyeon Lee, Soo Jeong Nam, Chan-Young Ock, Jae-Woo Moon, Chong Woo Yoo, Geon Kook Lee, Ji-Youn Han. J Thorac Oncol 2018
50
21


Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, Emiliano Calvo, Paolo A Ascierto, Akin Atmaca, Naiyer A Rizvi, Fred R Hirsch, Giovanni Selvaggi, Joseph D Szustakowski,[...]. Cancer Cell 2018
446
21

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Fred R Hirsch, Abigail McElhinny, Dave Stanforth, James Ranger-Moore, Malinka Jansson, Karina Kulangara, William Richardson, Penny Towne, Debra Hanks, Bharathi Vennapusa,[...]. J Thorac Oncol 2017
800
21

High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
Yih-Leong Chang, Ching-Yao Yang, Yen-Lin Huang, Chen-Tu Wu, Pan-Chyr Yang. Oncotarget 2017
39
21

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
21

The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
L Bonanno, A Pavan, M V Dieci, E Di Liso, M Schiavon, G Comacchio, I Attili, G Pasello, F Calabrese, F Rea,[...]. Eur J Cancer 2018
47
21

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
21

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
21

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.
Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Lionel Uwer, José Hureaux, Florian Guisier, Delphine Carmier, Jeannick Madelaine, Josiane Otto,[...]. J Thorac Oncol 2019
83
21

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
21

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
Hyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, Jan H M Schellens, Steven Kao, Wilson H Miller, Jean-Pierre Delord, Bo Gao, David Planchard, Maya Gottfried,[...]. J Thorac Oncol 2020
107
21


PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.
Haidong Tang, Yong Liang, Robert A Anders, Janis M Taube, Xiangyan Qiu, Aditi Mulgaonkar, Xin Liu, Susan M Harrington, Jingya Guo, Yangchun Xin,[...]. J Clin Invest 2018
247
17

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
17

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Sandip Pravin Patel, Razelle Kurzrock. Mol Cancer Ther 2015
17

Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer.
Julie George, Motonobu Saito, Koji Tsuta, Reika Iwakawa, Kouya Shiraishi, Andreas H Scheel, Shinsuke Uchida, Shun-Ichi Watanabe, Ryo Nishikawa, Masayuki Noguchi,[...]. Clin Cancer Res 2017
75
17

PD-L1 and c-MET expression and survival in patients with small cell lung cancer.
Lulu Miao, Yunyun Lu, Yanjun Xu, Gu Zhang, Zhiyu Huang, Lei Gong, Yun Fan. Oncotarget 2017
28
17

Small-cell lung cancer: what we know, what we need to know and the path forward.
Adi F Gazdar, Paul A Bunn, John D Minna. Nat Rev Cancer 2017
274
17

Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Anna Sophie Berghoff, Gerda Ricken, Dorothee Wilhelm, Orsolya Rajky, Georg Widhalm, Karin Dieckmann, Peter Birner, Rupert Bartsch, Matthias Preusser. J Neurooncol 2016
66
17

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
T A Chan, M Yarchoan, E Jaffee, C Swanton, S A Quezada, A Stenzinger, S Peters. Ann Oncol 2019
708
17

Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll. Cancer Cell 2015
17

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
Daniel Carvajal-Hausdorf, Mehmet Altan, Vamsidhar Velcheti, Scott N Gettinger, Roy S Herbst, David L Rimm, Kurt A Schalper. J Immunother Cancer 2019
53
17

PD-L1 expression in neuroendocrine tumors of the lung.
Kenjiro Tsuruoka, Hidehito Horinouchi, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Keisuke Asakura, Kazuo Nakagawa, Hiroyuki Sakurai,[...]. Lung Cancer 2017
72
17

Current standards for clinical management of small cell lung cancer.
Anna F Farago, Florence K Keane. Transl Lung Cancer Res 2018
80
13

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Heng Lin, Shuang Wei, Elaine M Hurt, Michael D Green, Lili Zhao, Linda Vatan, Wojciech Szeliga, Ronald Herbst, Paul W Harms, Leslie A Fecher,[...]. J Clin Invest 2018
242
13

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
Joachim von Pawel, Robert Jotte, David R Spigel, Mary E R O'Brien, Mark A Socinski, Jörg Mezger, Martin Steins, Léon Bosquée, Jeffrey Bubis, Kristiaan Nackaerts,[...]. J Clin Oncol 2014
181
13

Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
John R Eckardt, Joachim von Pawel, Jean-Louis Pujol, Zsolt Papai, Elisabeth Quoix, Andrea Ardizzoni, Ruth Poulin, Alaknanda J Preston, Graham Dane, Graham Ross. J Clin Oncol 2007
214
13

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
13

Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer.
T Yazawa, H Kamma, M Fujiwara, M Matsui, H Horiguchi, H Satoh, M Fujimoto, K Yokoyama, T Ogata. J Pathol 1999
63
13

Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma.
Takuya Yazawa, Takaaki Ito, Hiroshi Kamma, Takehisa Suzuki, Koji Okudela, Hiroyuki Hayashi, Hisashi Horiguchi, Takesaburo Ogata, Hideaki Mitsui, Masaichi Ikeda,[...]. Am J Pathol 2002
35
13

Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer.
Tian Tian, Xiaobin Gu, Bo Zhang, Yang Liu, Chao Yuan, Lijuan Shao, Yajun Guo, Kexing Fan. Cancer Biomark 2015
37
13

Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate.
Wei Wang, Philip Hodkinson, Fiona McLaren, Alison MacKinnon, William Wallace, Sarah Howie, Tariq Sethi. Int J Cancer 2012
63
13

Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer.
A Doyle, W J Martin, K Funa, A Gazdar, D Carney, S E Martin, I Linnoila, F Cuttitta, J Mulshine, P Bunn. J Exp Med 1985
374
13

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.
Ramaswamy Govindan, Nathan Page, Daniel Morgensztern, William Read, Ryan Tierney, Anna Vlahiotis, Edward L Spitznagel, Jay Piccirillo. J Clin Oncol 2006
13

Regulation and Function of the PD-L1 Checkpoint.
Chong Sun, Riccardo Mezzadra, Ton N Schumacher. Immunity 2018
703
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.